On Wednesday, CNH Industrial, (NYSE:CNHI)’s shares surged 7.65% to $8.87, following the farm and construction machinery company’s general meeting.
At the general meeting the shareholders of CNH Industrial re-elected all 11 members of the company’s board of directors. The shareholders also granted the board the authority to repurchase up to 10% of the company’s outstanding common shares.
The repurchase authorization is accessible to the board of directors, and doesn’t place the obligation on the company to repurchase its own shares.
CNH Industrial also declared a 20 euro cent dividend at the annual meeting. The dividend is payable on April 29 to all shareholders of record as of the close of business on April 21. The ex-dividend date is set for April 20.
CNH Industrial N.V. designs, produces, markets, sells, and finances agricultural and construction equipment, trucks, commercial vehicles, buses, and specialty vehicles, engines, transmissions, and axles worldwide.
Cameco Corporation (NYSE:CCJ)’s shares gained 7.56% to $16.36, during the last trading session on Wednesday.
Cameco Corporation, declared that Cameco Inc. has signed a supply contract with the Department of Atomic Energy of India to provide 7.1 million pounds of uranium concentrate under a long-term contract through 2020.
The contract is Cameco Inc.’s first with India which is the world’s second fastest growing market for nuclear fuel. India operates 21 nuclear reactors providing 6,000 megawatts of nuclear capacity meeting about 3% of the country’s electricity needs. Another six reactors totaling 4,300 megawatts are under construction and planned to come online by 2017. By 2032, India anticipates to have 45,000 megawatts of nuclear capacity.
Export of Canadian uranium to India for the generation of electricity is authorized by the Canada-India Nuclear Co-operation Contract which came into force in September 2013.
Cameco Corporation produces and sells uranium worldwide. The company operates through Uranium, Fuel Services, and NUKEM segments. The Uranium segment is involved in the exploration for, mining, and milling of uranium concentrates.
At the end of Wednesday’s trade, Cloud Peak Energy Inc. (NYSE:CLD)’s shares gained 7.54% to $6.42.
Cloud Peak Energy, plans to declare its first quarter 2015 financial results on April 30, 2015, after the markets close.
A conference call with administration is planned at 5:00 p.m. ET on April 30, 2015 to review the results and current business conditions.
Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The company operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments. It produces and sells sub-bituminous thermal coal with low sulfur content primarily to electric utilities operating in the United States and internationally.
Finally, Clovis Oncology, Inc. (NASDAQ:CLVS), ended its Wednesday’s trading session with 7.53% gain, and closed at $92.85, hitting its highest level, after analysts at Goldman Sachs (GS) nearly doubled the company’s price target to $117 from $68 before the opening bell.
The upgraded outlook is in response to the firm’s adjusted peak sales projection of the company’s developmental lung cancer drug, Rocilentinib, to $2 billion from $1.5 billion. The firm anticipates the company to file for FDA approval of the drug as a second-line lung cancer therapy by the middle of this year with an eye for a launch date in the first quarter of 2016.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which comprise Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
